COMMUNIQUÉS West-GlobeNewswire

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
10/09/2026
Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
10/09/2026
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001 in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity [...]
Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer
10/09/2026
Dr. Walker joins to lead Scenic's transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a [...]
Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34
10/09/2026
Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent [...]
Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors
10/09/2026
Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General Meeting VANCOUVER, British Columbia, Sept. 10, [...]
EPIK Biosciences Advances Combination Medicines Across Ketamine-Based and DXM-Based Programs, Supported by 34 Provisional Drug Patent Applications
10/09/2026
Over 20 filings are ketamine-based and over 5 are dextromethorphan (DXM)-based; applications total more than 2,700 pages of scientific and technical data; Company expects to disclose the full combination portfolio later [...]
Syngenta et Amoéba ont conclu un accord de distribution exclusif en Europe pour proposer aux céréaliers une innovation biofongicide
10/09/2026
Bâle (Suisse) et Chassieu (France) , 10 sept. 2026 (GLOBE NEWSWIRE) -- Cet accord exclusif couvrira le marché des céréales dans l’Union européenne, au Royaume-Uni, en Ukraine et en Suisse, avec les premiers lancements [...]
Syngenta and Amoéba Seal Exclusive European Distribution Deal, Aiming to Bring a Breakthrough Biofungicide to Cereal Growers
10/09/2026
Basel, Switzerland and Chassieu, France, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The exclusive agreement will span the cereals market across the European Union, the United Kingdom, Ukraine and Switzerland, with first market [...]
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
10/09/2026
Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastructure, surgeon relationships [...]
Kestra Names Daniel Finney Vice President of Research & Development
10/09/2026
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named [...]
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
10/09/2026
ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of [...]
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
10/09/2026
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully priced its offering of approximately $4.9 billion ( [...]
Ethris and EIB sign €30M financing under HERA Invest to advance further clinical development of broad-spectrum nasal antiviral
10/09/2026
Funding will support Ethris in the development of its portfolio of respiratory mRNA products for chronic respiratory diseases and pandemic preparedness. EIB’s financing is backed up by DG HERA, as part of the European [...]
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
10/09/2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study showing [...]
VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing Licence
10/09/2026
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first [...]
Hexiris Ophthalmics to Present First-in-Human OBi Glaucoma Data at Five Fall Meetings, Beginning with the Ophthalmology Futures Forum in London
10/09/2026
Physician-founded company will bring its office-based interventional glaucoma platform to Ophthalmology Futures, ESCRS, Sally Letson, CGS and AAO 2026 DIEPPE, New Brunswick, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Hexiris [...]
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
10/09/2026
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout [...]
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
10/09/2026
Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal [...]
Zoher F. Kapasi, PhD, PT, Named Provost of Thomas Jefferson University
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Thomas Jefferson University has announced the appointment of Zoher F. Kapasi, PhD, PT, as its next Provost effective Nov. 1, 2026. With extensive experience in higher [...]

Pages